Please assess the completion status of the following clinical trial:

Trial Title: Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent GEP NET Ki 67 ≤ 10 %~* Histologically or cytologically confirmed GEP NET~* Appearance of carcinoid syndrome maximum 6 months before the inclusion~* Evaluable or measurable disease (RECIST 1.1) WHO ECOG performance status 0-2~* Positive somatostatin receptor scintigraphy~* \>18 years~* Life expectancy of at least 12 weeks~Exclusion Criteria:~* Uncontrolled concurrent disease which prevents the adequate management and follow-up of the NET.~* Previous malignancy in the last past 3 years except malignancies estimated as completely cured.~* Current pregnancy or breast feeding~* Concomitant anti-tumoral treatment, except external beam radiotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): All patients will be treated with octreotide LAR intramuscular injections at maximum doses of 60 mg every 4 weeks or a frequency up to 30 mg octreotide LAR each 2 weeks. Change of dose or frequency is left at the discretion of the investigator until symptom control is obtained.

Based on this trial design, predict the completion outcome and termination type (if applicable).